A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
A 2015 Australian survey on levels of crucial nutrients, including vitamin B12, found many had suboptimal levels
Satisfied with my purchased Great price and works great
Free consult Book online Injectables, advanced skin tech, and facials under one roof
What we can say with confidence is that the compounds target non-overlapping pathways, show no receptor competition in pharmacological models, and have individual safety profiles that don't predict catastrophic interaction
FAQs Why should I choose an injection over an OTC supplement